Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD

NCT ID: NCT05799664

Last Updated: 2024-01-24

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-07-04
• Study Completion Date: 2026-08-31

Brief Summary

The objective of this trial is to evaluate the safety and effectiveness of Targeted Lung Denervation (TLD) for COPD patients using the lung denervation radiofrequency ablation device.

Conditions

COPD

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Experimental group

Patients will be treated with TLD and standard of care (per GOLD guideline).

Group Type: EXPERIMENTAL

TLD

Intervention Type: DEVICE

Patients allocated to experimental group will receive TLD therapy during which radiofrequency energy will be delivered to vagus nerve surrounding airway under bronchoscopy.

Standard of care

Intervention Type: OTHER

Patients will also receive standard of care that meet the recommendations of GOLD guideline.

Control group

Patients will undergo sham TLD procedure and be treated with standard of care (per GOLD guideline).

Group Type: SHAM_COMPARATOR

Sham TLD procedure

Intervention Type: OTHER

Patients allocated to control group will receive sham TLD procedure during which catheter will be placed in all treatment locations with no radiofrequency energy delivered.

Standard of care

Intervention Type: OTHER

Patients will also receive standard of care that meet the recommendations of GOLD guideline.

Interventions

TLD

Patients allocated to experimental group will receive TLD therapy during which radiofrequency energy will be delivered to vagus nerve surrounding airway under bronchoscopy.

Intervention Type: DEVICE

Sham TLD procedure

Patients allocated to control group will receive sham TLD procedure during which catheter will be placed in all treatment locations with no radiofrequency energy delivered.

Intervention Type: OTHER

Standard of care

Patients will also receive standard of care that meet the recommendations of GOLD guideline.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Participants aged ≥40 and ≤ 75 years;

2. Diagnosis of COPD with post-bronchodilator PFT parameters FEV1/FVC<70% and 20% ≤ FEV1 ≤ 60% of predicted; if FEV1<30%pred, PaCO2≤50mmHg;

3. CAT ≥ 10 or mMRC ≥2;

4. Non-smoking for a minimum of 2 months prior to consent and agrees to not smoke for the duration of the clinical investigation;

5. Recent participation in a formal pulmonary rehabilitation program should have occurred ≥3 months prior to consent; if participants are currently enrolled in a maintenance program, they should agree to continue their current program through their 12-month follow-up visit;

6. Documented history of taking standard medication (consistent with GOLD guideline<2022>) for ≥12 months at the time of consent;

7. Received an influenza vaccine within the 12 months prior to consent or agrees to obtain an influenza vaccine during the clinical investigation, and agrees to annual influenza vaccines for the duration of the clinical investigation;

8. Resting SpO2 ≥ 89% at the time of screening;

9. Willing, able, and agrees to complete all protocol required baseline and follow-up testing assessments including finishing the Patient Diary;

10. Able to understand the purpose of the clinical investigation, agree to participate in the trial and able to complete the informed consent signature.

Exclusion Criteria

1. BMI < 18 or > 35;

2. Asthma as defined by the GINA guideline (2022);

3. Patient has been previously diagnosed with a non-COPD active lung disease (e.g., active tuberculosis);

4. Patient has a medical history of pneumothorax;

5. Known contraindication or allergy to medications required for bronchoscopy or general anesthesia that cannot be medically controlled;

6. Recent respiratory infections or COPD exacerbation in preceding 4 weeks;

7. Malignancy treated with radiation or chemotherapy within 2 years of consent;

8. Daily use of > 10 mg of prednisone or its equivalent at the time of consent;

9. Recent (within 3 months of consent) opioid use;

10. Known gastrointestinal motility disorder or previous abdominal surgical procedure on stomach, esophagus, or pancreas

11. Has an implantable electronic device;

12. Previous or planned pulmonary or thoracic surgery (including but not limited to: pneumonectomy, lung transplantation, pulmonary medical device intervention < e.g. pulmonary valve implantation, bronchial thermal ablation (BT), etc. >) during this trial;

13. Myocardial infarction within last 6 months, EKG with evidence of life-threatening arrhythmias or acute ischemia, pre-existing documented evidence of a LVEF < 45%, stage C or D (ACC/AHA) or Class III or IV (NYHA) congestive heart failure, or any other cardiac findings that make the participant an unacceptable candidate for a bronchoscopic procedure utilizing general anesthesia;

14. High risk of pulmonary hypertension according to clinical assessment, defined as pulmonary artery systolic pressure estimated by echocardiogram to be > 50 mmHg;

15. Pulmonary nodule or other lesions thought to be at high risk of malignancy;

16. Clinically relevant bronchiectasis, defined as severe single lobe or multilobar bronchial wall thickening associated with airway dilation on CT scan leading to cough, intractable expectoration and repeated hemoptysis lasting for several days;

17. In the opinion of the Investigator, use of the TLD devices is not feasible, for example, due to screening chest CT scan reveals severe emphysema or bronchi anatomy cannot be fully treated with available catheter sizes: severe bullous disease (> 1/3 hemithorax) or site discovery of a mass that requires treatment;

18. A GCSI total symptom score ≥ 18.0 prior to treatment;

19. Any disease or condition that might interfere with completion of a procedure or this study (e.g., life expectancy< 1 years);

20. Women of childbearing potential must have a negative pregnancy test (blood or urine) pre-treatment and agree not to become pregnant for the duration of the study

21. Participated in any clinical trial and received experimental treatment within 3 months before the screening visit.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hangzhou Broncus Medical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Fengming Luo, M.D.

Role: PRINCIPAL_INVESTIGATOR

West China Hospital

Locations

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Liheng Xie

Role: CONTACT

medicalaffairs@broncuschina.com

+8613916444591

Facility Contacts

Fengming Luo, M.D

Role: primary

luofengming@hotmail.com

+8618980601355

Other Identifiers

BC-TLD-02

Identifier Type: -

Identifier Source: org_study_id